FILTER
FILTERED INTERVIEW RESULTS
Dr. Benedito Paulo Manuel
DIRECTOR GENERAL, SOCIEDADE MINEIRA DE CATOCA LDA
Sociedade Mineira de Catoca comments on the developments affecting Angola’s mining industry.
Tim Livesey
CEO, ORIOLE RESOURCES
Oriole Resources explains its ambitions exploring for gold in Cameroon and Senegal.
Chris McQuillan
DIRECTOR, PW NIGERIA MINING LIMITED (PWN MINING)
PW Nigeria Mining explains its move into Nigeria’s underdeveloped mining industry.
Stéphane Cervellera
WESTERN AFRICA MANAGER, TITANOBEL
Titanobel explains its plans to expand its explosive business around the world.
Olivier Terra
MANAGING DIRECTOR, BOLLORÉ TRANSPORT & LOGISTICS ZAMBIA
Bolloré Zambia comment on the logistics issues that they deal with in landlocked Zambia.
Todd Burns
PRESIDENT, CYPHER ENVIRONMENTAL
Cypher Environmental provides solutions for stabilizing roads and suppressing dust in an environmentally friendly manner.
Vincent Mascolo
CEO, IRON RIDGE RESOURCES
IronRidge’s focus on lithium and gold gives investors exposure to rapidly growing lithium technology markets while hedging prominent global economic uncertainty via a large gold exploration portfolio.
Paul Roberts
MANAGING DIRECTOR, PREDICTIVE DISCOVERY
Predictive Discovery explains progress at its Bankan discovery in Guinea, which holds a special place in the company’s West African portfolio.
James Wallbank
MANAGING PARTNER, IBAERA CAPITAL
Ibaera Capital explains its investment strategy as it opens a new and larger fund.
Dolores Biamou
MINING PROJECTS DIRECTOR AFRICA, BOLLORÉ LOGISTICS
Bolloré Logistics explains how it maintained supply chain continuity throughout the lock-down period.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
